A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy
Status: | Completed |
---|---|
Conditions: | Arthritis, Rheumatoid Arthritis |
Therapuetic Areas: | Rheumatology |
Healthy: | No |
Age Range: | 18 - 75 |
Updated: | 7/12/2018 |
Start Date: | October 2008 |
End Date: | December 2010 |
Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy
To assess the efficacy of LY2127399 versus placebo using American College of Rheumatology
(ACR)50 response scale at 24 weeks
(ACR)50 response scale at 24 weeks
Inclusion Criteria:
- Have given written informed consent
- Women must not be at risk to become pregnant during study participation
- Diagnosis of Rheumatoid Arthritis (RA)
- Current, regular use of Methotrexate, at a stable dose
- Other criteria to be reviewed by study doctor
Exclusion Criteria:
- Use of excluded medications(reviewed by study doctor)
- Have not failed biologic tumor necrosis factor-alpha (TNF-α) inhibitor therapy
- Have had recent or ongoing infection which, in the opinion of the study doctor put
patient at an unacceptable risk for participation in the study
- Evidence of tuberculosis
- Have systemic inflammatory condition other than RA, such as juvenile RA, Crohn's
disease, ulcerative colitis, psoriatic arthritis or seronegative spondyloarthropathy
- Other criteria to be reviewed by study doctor
We found this trial at
7
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials